Gonadorelin 2mg is a synthetic decapeptide identical in sequence to natural gonadotropin-releasing hormone (GnRH). Supplied as a high-purity lyophilized research compound, it is utilized in laboratory settings to investigate hypothalamic-pituitary-gonadal (HPG) axis signaling, gonadotropin receptor kinetics, and downstream luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion dynamics.
Gonadorelin 2mg is a synthetic decapeptide identical in sequence to natural gonadotropin-releasing hormone (GnRH). Supplied as a high-purity lyophilized research compound, it is utilized in laboratory settings to investigate hypothalamic-pituitary-gonadal (HPG) axis signaling, gonadotropin receptor kinetics, and downstream luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion dynamics.
Gonadorelin is a synthetic 10-amino-acid peptide with the primary amino acid sequence Pyroglutamyl-Histidyl-Tryptophyl-Seryl-Tyrosyl-Glycyl-Leucyl-Arginyl-Prolyl-Glycinamide (Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2). With a molecular formula of C55H75N17O13 and a molecular weight of approximately 1182.3 g/mol, the molecule features a N-terminal pyroglutamic acid residue and a C-terminal glycinamide modification. These terminal modifications protect the peptide against rapid enzymatic degradation by specific aminopeptidases, allowing researchers to observe its intact binding interactions with targeted receptor populations in vitro.
In chemical structure, Gonadorelin is molecularly identical to the endogenous neurohormone GnRH produced by hypothalamic neurons. When evaluating raw materials across our catalog of all peptides, maintaining absolute fidelity to native structural sequences is vital for reproducibility in endocrine signaling models. The peptide exhibits high solubility in aqueous solutions, making it well-suited for controlled reconstitution protocols in preclinical testing.
The primary mechanism of action for Gonadorelin centers on its high-affinity binding to the G-protein coupled Gonadotropin-Releasing Hormone Receptor (GnRHR) located on the plasma membrane of anterior pituitary gonadotrope cells. Preclinical assays demonstrate that upon binding, Gonadorelin activates the Gq/11 protein subunit, which subsequently stimulates phospholipase C (PLC). This enzymatic cascade hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).
The generation of IP3 induces rapid intracellular calcium ion release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). Together, these intracellular messengers initiate exocytosis of pre-stored secretory vesicles containing luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Research models investigating hpg axis signaling rely on this precise biochemical mechanism to evaluate differential gonadotropin gene expression and pulsatile secretion dynamics under controlled experimental parameters.
In vitro and animal models have extensively investigated the dual behavior of Gonadorelin based on exposure pattern and administration frequency. Preclinical rodent studies indicate that pulsatile administration of Gonadorelin at specific hourly intervals maintains receptor sensitivity and promotes continuous, sustained synthesis and release of LH and FSH. Conversely, continuous or high-dose exposure induces severe receptor desensitization through rapid receptor phosphorylation, arrestin recruitment, and subsequent endocytosis of the GnRH receptor complex.
These preclinical findings highlight the central role of receptor turnover rates in neuroendocrine research. By utilizing high-purity gonadorelin 2mg, research groups can fine-tune pulsatile perifusion assays or cell culture systems to measure downstream cellular responses without interference from peptide impurities or endotoxin contamination.
When designing reproductive endocrinology or neurohormonal experiments, investigators frequently compare native sequence decapeptides with modified, long-acting synthetic analogs. While Gonadorelin shares the exact natural amino acid sequence of GnRH, synthetic analogs such as triptorelin 2mg, buserelin, and leuprolide incorporate specific D-amino acid substitutions at position 6 and ethylamide modifications at the C-terminus.
These structural modifications significantly alter the compound's binding affinity and enzymatic resistance. For instance, preclinical comparative data show that while Gonadorelin exhibits a short biological half-life in vitro due to rapid clearance by neutral endopeptidases, analogs like triptorelin possess up to 100-fold higher binding potency and extended receptor occupancy. Choosing between native Gonadorelin and stabilized analogs depends primarily on whether the experimental model seeks to evaluate natural physiological pulsation or sustained receptor suppression.
To preserve the structural integrity of lyophilized Gonadorelin 2mg, standard laboratory storage procedures must be strictly enforced. Upon receipt, unopened vials should be stored in a freezer maintained at -20°C or -80°C, protected from light and ambient moisture. Under these cold-storage conditions, the lyophilized cake remains stable for extended research timelines.
Reconstitution should be conducted inside a certified laminar flow hood utilizing aseptic technique. For standard laboratory assays, sterile bacteriostatic water or laboratory-grade phosphate-buffered saline (PBS, pH 7.4) is recommended as the diluent. Researchers should slowly drip the solvent along the inner glass wall of the vial and gently swirl the contents until fully dissolved. Vigorous agitation or vortexing must be avoided to prevent peptide shear stress and denaturation. For detailed protocol recommendations, consult our technical guide on peptide reconstitution.
Accurate concentration calculations are vital for cell culture dosing and binding assays. Reconstituting a 2mg vial of Gonadorelin (molecular weight ~1182.3 g/mol) with 2.0 mL of sterile diluent yields a working solution concentration of 1.0 mg/mL, which corresponds to a molar concentration of approximately 0.846 mM (846 µM).
Following initial reconstitution, working aliquots should be divided into single-use polypropylene microtubes to prevent degradation caused by repeated freeze-thaw cycles. Reconstituted liquid aliquots should be stored at -20°C and utilized within target research timeframes to ensure experimental consistency.
PX1 Research enforces rigid quality assurance protocols for every lot of Gonadorelin 2mg manufactured in our USA-based partner facilities. To guarantee reliable data for institutional studies, each lot undergoes comprehensive analytical characterization prior to distribution.
Purity is verified using High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum purity threshold of ≥98%. Molecular weight identity is confirmed via Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) or ESI-MS. Furthermore, because bacterial endotoxins can confound cell culture viability and receptor signaling data, our compounds undergo rigorous Limulus Amebocyte Lysate (LAL) testing to confirm low endotoxin levels suitable for delicate in vitro procedures.
Reproducibility in preclinical science depends entirely on supplier transparency and lot-to-lot consistency. Researchers evaluating peptides should always inspect third-party Certificates of Analysis (COAs) generated by ISO 17025 accredited testing laboratories. A valid COA must display clear HPLC chromatograms, mass spectral peaks matching theoretical molecular mass, and quantifiable endotoxin data.
PX1 Research makes full lot-specific documentation accessible for every compound in our catalog. Academic laboratories, biotechnology organizations, and corporate institutions seeking bulk quantities for ongoing protocol series can access dedicated ordering support through our wholesale portal or review broader mechanism summaries in our peptides research library.
What is Gonadorelin 2mg intended for?
Gonadorelin 2mg is supplied strictly as a high-purity research peptide intended for in vitro, cell culture, and preclinical laboratory experimentation. It is not for human or clinical use.
What is the sequence and molecular weight of Gonadorelin?
Gonadorelin has the amino acid sequence Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 and a chemical molecular weight of approximately 1182.3 g/mol.
How does Gonadorelin differ from synthetic GnRH agonists like Triptorelin?
Gonadorelin possesses the exact primary sequence of native GnRH and exhibits a shorter biological half-life. Agonists like Triptorelin feature amino acid modifications (e.g., D-Trp at position 6) that significantly increase binding affinity and metabolic stability.
What diluent should be used for reconstituting Gonadorelin in the lab?
Laboratory protocols typically utilize sterile bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4) depending on the requirements of the downstream assay.
How should reconstituted Gonadorelin be stored?
Once reconstituted, Gonadorelin should be divided into single-use aliquots and stored at -20°C or colder to preserve peptide stability and avoid repeated freeze-thaw degradation.
How does PX1 Research verify the purity of Gonadorelin 2mg?
Every lot of Gonadorelin 2mg manufactured for PX1 Research undergoes RP-HPLC testing for purity (≥98%), mass spectrometry for identity confirmation, and LAL assays for endotoxin quantification at independent ISO 17025 accredited labs.
What receptor pathway does Gonadorelin target in vitro?
Gonadorelin binds directly to the Gonadotropin-Releasing Hormone Receptor (GnRHR), triggering Gq/11 protein coupling, PLC activation, intracellular calcium mobilization, and PKC signaling.
Where is PX1 Research Gonadorelin manufactured and shipped from?
PX1 Research compounds are manufactured in GMP-compliant USA facilities and dispatched directly from our distribution hubs in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.